
CYCC
Healthcare · Biotechnology · $14.3M market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2024
EPS trend, 90 days to now · 30-day revisions 1 up, 0 down
Beat estimates in 3 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Aug 13, 2025 | Time not confirmed | — | -0.98 | — |
| May 12, 2025 | Before the open | -6.08 | -0.34 | +94.3% |
| Nov 12, 2024 | After the close | -129.60 | -43.20 | +66.7% |
| Aug 14, 2024 | After the close | -1.43 | -0.72 | +49.7% |
| May 14, 2024 | After the close | -4.74 | -2.27 | +52.1% |
| Mar 19, 2024 | After the close | -5.89 | -6.23 | -5.8% |
| Nov 13, 2023 | After the close | -0.36 | -0.49 | -36.1% |
| Aug 9, 2023 | After the close | -0.50 | -0.44 | +12.0% |
| May 11, 2023 | After the close | -0.66 | -0.47 | +28.8% |
| Mar 6, 2023 | After the close | -0.48 | -0.60 | -25.0% |
| Nov 9, 2022 | After the close | -0.56 | -0.42 | +25.0% |
| Aug 10, 2022 | After the close | -0.63 | -0.46 | +27.0% |
| May 11, 2022 | After the close | -0.68 | -0.42 |
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer medicines based on cell cycle, transcriptional regulation, epigenetics, and mitosis control biology in the United States. Its lead product Plogosertib or plogo, a solid tumors and hematological malignancies, which is in Phase 1/2 clinical trial. The company was founded in 1996 and is headquartered in Kuala Lumpur, Malaysia.
| +38.2% |
| Mar 28, 2022 | After the close | -0.65 | -0.54 | +16.9% |
| Nov 10, 2021 | After the close | -0.65 | -0.54 | +16.9% |
| Aug 11, 2021 | After the close | -0.50 | -0.56 | -12.0% |
| May 12, 2021 | After the close | -0.49 | -0.50 | -2.0% |
| Feb 25, 2021 | After the close | -0.51 | -1.34 | -162.7% |
| Nov 11, 2020 | After the close | -0.55 | -0.47 | +14.5% |
| Aug 12, 2020 | After the close | -0.47 | -0.58 | -23.4% |
| May 12, 2020 | After the close | -2.90 | -1.48 | +49.0% |
| Feb 26, 2020 | After the close | -2.70 | -2.80 | -3.7% |
| Nov 13, 2019 | After the close | -3.13 | -2.20 | +29.7% |
| Aug 13, 2019 | After the close | -3.13 | -2.20 | +29.7% |
| May 14, 2019 | After the close | -4.10 | -2.80 | +31.7% |
| Mar 27, 2019 | After the close | -3.47 | -3.40 | +2.0% |
| Nov 12, 2018 | After the close | -3.40 | -3.60 | -5.9% |
| Aug 9, 2018 | After the close | -2.40 | -3.20 | -33.3% |
| May 14, 2018 | After the close | -2.60 | -2.40 | +7.7% |
| Mar 28, 2018 | After the close | -0.73 | -3.20 | -338.4% |